Fiserv Forum, home of the Milwaukee Bucks, will host two rounds of the NCAA tournament this weekend. "Milwaukee's always been a great host, but since Fiserv Forum has opened, it's become a whole new ...

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

The China Development Forum, scheduled for March 23-24, is expected to host key figures such as Blackstone Inc.’s Steve ...

Healthcare companies rose as traders sought out sectors that are less vulnerable to swings in economic growth and inflation prospects.

We’re in a somewhat unusual economic predicament right now. On one hand, inflation remains high (at least compared to the ...

The researchers identified 1248 major structural birth defects among 78,052 pregnancies: 1049 in unvaccinated people and 199 in vaccinated people (160.6 and 156.4 per 10,000 live births, respectively) ...

Pfizer Canada’s IXIFI (infliximab for injection) will be available in Canada as of April 1, 2025. IXIFI is a biosimilar to Remicade (infliximab). It was approved by ...

We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look ...

Pfizer’s CEO Albert Bourla has revamped sales tactics, leading to a 31% rise in U.S. sales of Nurtec migraine medication, reports The Wall Street Journal.

Getting a headache and feeling sick are common side-effects for many medicines. Indulging in risky sexual behavior or ...

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...